Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$77,065.00-1.18%ETH$2,470.33+0.03%GOLD$4,386.00-0.48%OIL$99.65-2.76%
Smart Investors Daily
NS

AMEX · NSRX

Nasus Pharma Ltd.

Healthcare · Biotechnology

$3.35

Down-$0.20 (-5.63%)

Updated Sep 11, 2026, 10:08 AM

SID Score

3.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
58.89M
P/E ratio
-38.44
Dividend yield
0.00%
52-week range
$1.98 – $5.20
Volume
10.72K
Avg. volume
13.21K

Price performance

NSRX price history

1M range · 20 trading sessions · Daily adjusted prices

NSRX closed at $3.35 after 20 trading sessions, up 4.69% for the selected period.

Last close
$3.35
Period change
+4.69%
Period low
$3.20
Period high
$4.10
Daily close
View OHLC price history
NSRX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$3.16$3.4769$3.16$3.3510.72K
Sep 9, 2026$3.47$3.565$3.17$3.554.44K
Sep 8, 2026$3.53$3.9731$3.47$3.888.68K
Sep 4, 2026$3.5296$3.735$3.5296$3.735829.62
Sep 3, 2026$3.515$3.765$3.23$3.7515.1K
Sep 2, 2026$4.0368$4.0368$3.68$3.771.89K
Sep 1, 2026$3.85$4.08$3.43$3.82515.68K
Aug 31, 2026$3.9017$4.10$3.87$4.0844.66K
Aug 28, 2026$3.985$4.10$3.9838$4.1014.57K
Aug 27, 2026$4.05$4.10$4.05$4.108.83K
Aug 26, 2026$4.09$4.09$3.8688$4.054.46K
Aug 25, 2026$4.08$4.10$3.99$4.1010.21K
Aug 24, 2026$3.98$4.07$3.765$4.0717.39K
Aug 21, 2026$3.805$4.00$3.655$4.0029.9K
Aug 20, 2026$3.665$3.85$3.51$3.8511.25K
Aug 19, 2026$3.15$3.86$3.15$3.8439.07K
Aug 18, 2026$3.65$3.75$3.3681$3.6518.69K
Aug 17, 2026$3.70$3.70$3.4153$3.703.59K
Aug 14, 2026$3.20$3.64$3.20$3.6227.5K
Aug 13, 2026$3.08$3.49$3.05$3.206.84K

Latest NSRX news

The latest Smart Investors Daily articles mentioning NSRX.

Stock researchCompany · Overview

NSRX research

Overview

Company profile and research snapshot.

Company profile

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$22.00
Implied upside
—
Analysts
—
NSRX recent ratings
DateFirmRatingTarget
Mar 26, 2026CitizensMarket Outperform—
Dec 18, 2025CitizensMarket Outperform—
Sep 29, 2025Laidlaw & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 8, 2026

Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

TEL AVIV, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus", “Nasus Pharma” or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that the Company’s management team will participate and present in the H.C. Wainwright 28th Annual Global Investment Conference, to be held September 14-16, 2026 in New York, NY, at the Lotte New York Palace hotel. The Company’s presentation will be avai

Benzinga · Aug 17, 2026

Nasus Pharma H1 EPS $(0.54) Misses $(0.20) Estimate

Nasus Pharma (AMEX:NSRX) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.20) by 170 percent. This is a 217.65 percent decrease over losses of $(0.17) per share from the

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By